Prostate cancer medicine hailed as a "milestone" breakthrough may not be available to every patient after a revision of the drug guidelines, according to the NHS.
Men in England who have already been treated with a new-generation cancer drug would not be eligible for Enzalutamide, according to the National Institute for Health and Care Excellence (Nice).
Nice, the public body which decides the cost-effectiveness of medicines for NHS patients, said the new drug should not be used by patients who had already taken abiraterone.
Enzalutamide blocks molecular signals driving prostate cancer and improved survival by 30% in men who had not undergone chemotherapy.
A further 80% of men with advanced cancer had the progression delayed, even if the tumour had failed to respond to other treatments.
More top news
Australian businessman named as Alan Sugar's newest apprentice and winner of a £250,000 investment in his fledgling company.
The 270 victims of the Lockerbie bombing have been remembered today, 26 years to the day that they lost their lives in the air disaster.
Actress Billie Whitelaw, who starred in films including The Omen, has died aged 82.